Found 25 articles for: "PSOLAR"
Efficacy and Safety of Secukinumab in the Treatment of Psoriasis in Patients with Skin Phototypes IV to VI
August 2024 | Volume 23 | Issue 8 | Original Article | 600 | Copyright © August 2024
Background: There is a paucity of data on the treatment of psoriasis in patients with skin of color – a diverse population among whom variations in clinical features and hi...
Read MoreOutcomes for Psoriasis by Self-Identified Racial Groups in Ixekizumab Clinical Trials: A Pooled Analysis
February 2024 | Volume 23 | Issue 2 | Original Article | 17 | Copyright © February 2024
Background: Biologics have shown promising outcomes in psoriasis clinical trials. However, there is a paucity of data exploring the potential differences in outcomes between self...
Read MoreIntegrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel
June 2023 | Volume 22 | Issue 6 | Original Article | 588 | Copyright © June 2023
Background: Precision medicine utilizes an individual’s genomics to improve diagnosis, prognosis, and therapy. The joint American Academy of Dermatology and National Psoria...
Read MoreEvolving Concepts in Psoriasis: Special Considerations for Patients With Skin of Color, Skin Barrier Dysfunction, and the Role of Adjunctive Skin Care
October 2022 | Volume 21 | Issue 10 | Original Article | 1054 | Copyright © October 2022
Background: Despite considerable advances in our understanding of the pathogenesis and treatment of psoriasis, data pertaining to racial/ethnic variations, effects on barrier function...
Read MoreTherapies for Psoriasis: Clinical and Economic Comparisons
November 2020 | Volume 19 | Issue 11 | Original Article | 1101 | Copyright © November 2020
Background: Clinical and economic comparisons of therapies for plaque psoriasis are regularly updated following each new devel- opment in the field. With the recent availability of a ...
Read MoreSafety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies Errata
June 2020 | Volume 19 | Issue 6 | Editorials | 573 | Copyright © June 2020
Erratum for article "Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies." Retriev...
Read MoreSafety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Errata
June 2020 | Volume 19 | Issue 6 | Editorials | 571 | Copyright © June 2020
Erratum for article "Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)." Retrieved from Read More
Evaluation of Risk of Major Adverse Cardiovascular Events with Biologic Therapy in Patients with Psoriasis (Errata)
June 2020 | Volume 19 | Issue 6 | Editorials | 566 | Copyright © June 2020
Erratum for "Evaluation of Risk of Major Adverse Cardiovascular Events with Biologic Therapy in Patients with Psoriasis." Read More
Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?
April 2020 | Volume 19 | Issue 4 | Features | 436 | Copyright © April 2020
Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?...
Read MoreHalobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities
April 2020 | Volume 19 | Issue 4 | Original Article | 389 | Copyright © April 2020
Background: Plaque psoriasis can occur in all body regions, with the trunk and extremities among the most commonly affected areas. A fixed combination halobetasol propionate 0.01%/taz...
Read MoreNon-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
October 2019 | Volume 18 | Issue 10 | Editorials | 1059 | Copyright © October 2019
Patients with psoriasis are at increased risk of developing non melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).1,2 The risk is especiall...
Read MorePrescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database
August 2019 | Volume 18 | Issue 8 | Original Article | 745 | Copyright © August 2019
Introduction: Selecting a systemic therapy for patients with psoriasis is a complex process, based on a variety of factors including psoriasis severity, comorbid health conditions, ac...
Read MoreGrover’s Disease Treated With Total Skin Electron Beam Radiotherapy
April 2019 | Volume 18 | Issue 4 | Case Reports | 392 | Copyright © April 2019
Persistent Grover's disease can cause significant symptoms of pruritus thereby decreasing quality of life. Many patients undergo successful conservative management of their disease; however, a subset...
Read MoreTreatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review
April 2019 | Volume 18 | Issue 4 | Original Article | 387 | Copyright © April 2019
INTRODUCTION: Biologics have transformed the management of moderate-to-severe psoriasis. The risk of developing a malignancy during treatment is an important consideration, and many studies have b...
Read MoreAdverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis
November 2018 | Volume 17 | Issue 11 | Original Article | 1211 | Copyright © November 2018
OBJECTIVE: To assess the real-world risk of developing adverse medical conditions (AMCs) among patients with psoriasis treated with biologic therapies or conventional systemic/topical therapies (CST/t...
Read MoreLong-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
August 2018 | Volume 17 | Issue 8 | Original Article | 826 | Copyright © August 2018
Background: Due to the chronic nature of psoriasis, it is important to assess the sustained response of treatments over time. Objective: To assess the efficacy of continuous treatment with guselkumab...
Read MoreEvaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis
October 2017 | Volume 16 | Issue 10 | Original Article | 1002 | Copyright © October 2017
BACKGROUND: Psoriasis is associated with increased risk of major adverse cardiovascular events (MACE). OBJECTIVES: Compare MACE risk with biologics vs topical/phototherapy use. METHODS: Psoriasis Lo...
Read MoreAdalimumab in Chronic Plaque Psoriasis: A Clinical Guide
August 2017 | Volume 16 | Issue 8 | Original Article | 779 | Copyright © August 2017
Psoriasis is a common, inflammatory disease that manifests itself as lesions on the skin, which greatly impacts the physical and psychological wellbeing of those affected. The current goal of treat...
Read MoreEssential Truths for the Care and Management of Moderate-to-Severe Psoriasis
August 2015 | Volume 14 | Issue 8 | Original Article | 805 | Copyright © August 2015
Psoriasis is a systemic inflammatory disease. Effective management requires treatment with agents targeting inflammation in skin, joints, and other tissues. Biologics for psoriasis are directed at mor...
Read MoreSafety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
July 2015 | Volume 14 | Issue 7 | Original Article | 706 | Copyright © July 2015
BACKGROUND: Safety surveillance is needed for biologic therapies for psoriasis.
OBJECTIVE: To assess the risk of adverse events of special interest (AEoSIs) with ustekinumab and other psoriasis t...
Read MoreMedia and other results for: "PSOLAR"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.